Norwood Financial Corp Lowers Stock Holdings in Pfizer Inc. (NYSE:PFE)

Norwood Financial Corp trimmed its position in Pfizer Inc. (NYSE:PFE) by 57.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,843 shares of the biopharmaceutical company’s stock after selling 10,573 shares during the quarter. Norwood Financial Corp’s holdings in Pfizer were worth $218,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Clifford Swan Investment Counsel LLC raised its stake in Pfizer by 4.7% in the fourth quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock valued at $12,007,000 after purchasing an additional 18,611 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares in the last quarter. LifePlan Financial LLC purchased a new stake in Pfizer in the fourth quarter valued at approximately $255,000. Cantor Fitzgerald Investment Advisors L.P. purchased a new stake in Pfizer in the fourth quarter valued at approximately $16,166,000. Finally, KLCM Advisors Inc. raised its stake in Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after purchasing an additional 74,487 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on PFE shares. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Morgan Stanley increased their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Stock Up 0.7 %

Shares of Pfizer stock opened at $27.99 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.80. The stock has a market capitalization of $158.61 billion, a price-to-earnings ratio of -466.42, a P/E/G ratio of 1.09 and a beta of 0.70. The company’s 50 day moving average price is $27.90 and its 200-day moving average price is $27.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same quarter last year, the firm posted $1.23 earnings per share. The firm’s revenue was down 19.5% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.00%. The ex-dividend date is Friday, July 26th. Pfizer’s payout ratio is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.